| Title: | PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study |
| Journal: | Archives of Medical Science |
| Published: | 5 Jan 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/33488877/ |
| DOI: | https://doi.org/10.5114/aoms/127226 |
| URL: | ~Ehttps://www.archivesofmedicalscience.com/pdf-127226-60732?filename=PCSK9 genetic variants.pdf~ |
Publication 3405
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
INTRODUCTION: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious at reducing vascular disease, however questions remain about potential effects on cognitive function.</p>
METHODS: We examined the association of genetic variants in PCSK9 with continuous measures of cognitive ability in UK Biobank. Six independent polymorphisms in PCSK9 were used in up to 337,348 individuals.</p>
RESULTS: The PCSK9 allele score was associated with a lower risk of CHD, and weakly with worse log reaction time.</p>
CONCLUSIONS: We are unable to rule out meaningful associations of PCSK9 genetic variants with cognition, emphasising the potential need for continued pharmacovigilance for patients currently treated with PCSK9 inhibitors.</p>
8 Authors
- Donald M. Lyall
- Joey Ward
- Maciej Banach
- George Davey Smith
- Jason G. Gill
- Jill P. Pell
- Michael V. Holmes
- Naveed Sattar
1 Application
| Application ID | Title |
|---|---|
| 17689 | Genetic, environmental and lifestyle predictors of brain/cognitive-related outcomes. |
Enabling scientific discoveries that improve human health